Most Popular News Stories on OBR Daily
(Roche) Mar 26, 2018 - Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of overall survival (OS) at this interim analysis and showed that initial (first-line) treatment with the combination of TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) helped people with advanced non-squamous non-small cell lung cancer (NSCLC) live significantly longer compared with Avastin plus carboplatin and paclitaxel.
(American College of Surgeons) Mar 23, 2018 - For many years in the U.S., there has been tremendous variability in the treatment and outcomes for rectal cancer care.
(Washington Post/Kaiser Health News) Mar 27, 2018 - Patient portals often provide information without explanation and context.
(ASCO in Action) Apr 12, 2018 - An analysis published today in the American Society of Clinical Oncology’s (ASCO) Journal of Oncology Practice (JOP), suggests that including cancer drug costs in bundled payments under Medicare risks destabilizing the cancer care delivery environment.
(OMRF) Mar 28, 2018 - For many years, physicians have puzzled over why people with "clean" colonoscopies went on to develop colon cancer. New findings from the Oklahoma Medical Research Foundation may help explain why, and the discovery could lead to ways to detect these cancers earlier and more effectively.
(Reuters) Apr 5, 2018 - Medicare, the U.S. government healthcare program for the elderly and disabled, will pay hospitals close to its standard mark-up rate for administering cell therapy Yescarta for cancer outpatients, who will have a co-payment of nearly $80,000, according to the Centers for Medicare & Medicaid Services (CMS).
(Stanford Medicine/Scope blog) Apr 4, 2018 - A new study found that oncologists have divergent views on how to use “value” to guide cancer treatment recommendations.
(NBCNews.com) Apr 2, 2018 - New therapy seen as possible treatment for pancreatic cancer and triple-negative breast cancer, among others.
(Merck) Apr 9, 2018 - Merck, known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-042 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC, including nonsquamous or squamous histologies) met its primary endpoint of overall survival (OS).
(Penn Medicine) Apr 10, 2018 - Literature review finds increased risk of cancer, late stage cancer, and mortality with increasing wait time between a positive screening and start of diagnostic testing.